EDIT
Editas Medicine, Inc.
Nasdaq: EDIT · Cambridge, MA · Healthcare
$2.65+0.01 (+0.19%)Closed
Market Cap$261.3M
Cash$123.6Mmost recent
Runway16 mo$23.1M Q burn
P/E (TTM)—EPS $-1.80
52-Wk Range$1.66 – $4.15
Avg Volume2.2M3-month
Price & Trading Activity
Daily close with catalyst overlays and trading volume
$2.65-50.2%
Pipeline
Drug candidates sponsored by Editas Medicine · ClinicalTrials.gov
| Phase | Drug / Candidate | Indications | Status | Next Completion | Trials | |
|---|---|---|---|---|---|---|
| Phase 1 | EDIT-101 | Leber Congenital Amaurosis 10+6 more | Unknown | 2025-05-23past | 1 | |
| Phase 1 | EDIT-301 | Sickle Cell Disease+4 more | Active, not recruiting | 2025-09past | 2 | |
| N/A | Unnamed | Blindness+7 more | Completed | 2022-05-06past | 1 | |
| N/A | Unnamed | Sickle Cell Disease+2 more | Enrolling | 2040-08 | 1 |
Valuation
Risk-adjusted NPV
Loading pipeline…
Peer comparison
Cohort check
Gene editing · 5 tickers
Loading peers…
Cells tinted green are top-ranked in the cohort, red are worst-ranked.